Cargando…
Novel Biological Therapies for Severe Asthma Endotypes
Severe asthma comprises several heterogeneous phenotypes, underpinned by complex pathomechanisms known as endotypes. The latter are driven by intercellular networks mediated by molecular components which can be targeted by specific monoclonal antibodies. With regard to the biological treatments of e...
Autores principales: | Pelaia, Corrado, Pelaia, Giulia, Crimi, Claudia, Maglio, Angelantonio, Stanziola, Anna Agnese, Calabrese, Cecilia, Terracciano, Rosa, Longhini, Federico, Vatrella, Alessandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138687/ https://www.ncbi.nlm.nih.gov/pubmed/35625801 http://dx.doi.org/10.3390/biomedicines10051064 |
Ejemplares similares
-
Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma
por: Pelaia, Corrado, et al.
Publicado: (2021) -
Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma
por: Pelaia, Corrado, et al.
Publicado: (2021) -
Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13
por: Pelaia, Corrado, et al.
Publicado: (2022) -
Molecular Targets for Biological Therapies of Severe Asthma
por: Pelaia, Corrado, et al.
Publicado: (2020) -
Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma
por: Vatrella, Alessandro, et al.
Publicado: (2022)